Pathobiology and Treatment of Hepatitis Virus-Related Thrombocytopenia
2009

Hepatitis Virus-Related Thrombocytopenia

Sample size: 799 publication 10 minutes Evidence: moderate

Author Information

Author(s): Roberto Stasi, Chia Lian Wea, Kalkur Pallavi Lowe, Robert Shannon Muriel S.

Primary Institution: Department of Haematology, St George’s Hospital, London, UK

Hypothesis

Thrombocytopenia may be the only manifestation of viral hepatitis and should be considered in the differential diagnosis of primary immune thrombocytopenia.

Conclusion

Thrombocytopenia is commonly associated with chronic hepatitis C infection, and treatment with eltrombopag can effectively normalize platelet levels.

Supporting Evidence

  • Thrombocytopenia is a recognized complication of infections, including those from hepatotropic viruses.
  • Treatment of HCV infection often results in substantial improvement or complete recovery of thrombocytopenia.
  • Eltrombopag normalizes platelet levels in patients with thrombocytopenia associated with HCV-related chronic liver disease.

Takeaway

Some people with liver infections can have low platelet counts, and a medicine called eltrombopag can help raise those counts.

Methodology

The review summarizes various studies on thrombocytopenia associated with hepatitis C and other viral infections.

Potential Biases

Potential bias in the studies reviewed due to retrospective designs and varying definitions of thrombocytopenia.

Limitations

The review primarily focuses on chronic hepatitis C, with limited data on hepatitis B.

Participant Demographics

The studies included adult patients with chronic hepatitis C and immune thrombocytopenia.

Statistical Information

P-Value

P < 0.00001

Confidence Interval

95% CI, 1.4–2.3

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.4084/MJHID.2009.023

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication